top button
    Got Questions


Global IoT Summit 2018
Oct 31, 2018
The Leela Palace, Bangalore



    Connect to us
      Facebook Login
      Site Registration Why to Join

Facebook Login
Site Registration

Non-Small Cell Lung Cancer Therapeutics Market Share Explored in Latest Research

0 votes
2 views

The vendor landscape of the global non-small cell lung cancer therapeutics market features the presence of a number of players, but was dominated by Genentech, a Roche company, which accounted for nearly 36% of the overall market in 2014, observes a recent report by Transparency Market Research (TMR). The market is marked with a moderate level of competition and focus on the development of new and more effective varieties of drugs has increased from companies anticipating a better grip on the market. Strategic collaborations with the view of expanding geographical outreach and product portfolios is also a key strategy adopted by companies operating in the global non-small cell lung cancer therapeutics.

Some of the leading companies operating in the market are Novartis AG, Bristol-Myers Squibb, Celgene Corporation, AstraZeneca plc, Pfizer, Inc., Boehringer Ingelheim, and Eli Lilly and Company.

According to the report, the global non-small cell lung cancer therapeutics market will rise to a valuation of US$15.1 bn by 2023.

Get Sample with Latest Research @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=504

Asia Pacific Promising Excellent Growth Opportunities

Geographically, the market in Asia Pacific is expected to emerge as one of the leading contributors of revenue to the global market, thanks to the rising awareness regarding cancer and the active role of governments in the region in supporting the treatment of lung cancer through subsidized treatment and medicines in public healthcare centers. The region will continue to remain one of the most lucrative regional market for the field of non-small cell lung cancer therapeutics owing to the rising prevalence of lung cancer.

Based on drugs, the segment of angiogenesis inhibitors is expected to dominate in terms of demand as well as revenue contribution to the global market. This can be attributed to its effectiveness and the increased adoption of targeted therapies in a number of regional markets. The segment is expected to rise to a valuation of US$2,020.4 mn by 2023.

Rich Pipeline of Drugs and Continuous R&D Efforts Open Up Promising Growth Avenues for Market

The rising prevalence of lung cancer globally is naturally the leading cause driving the market for non-small cell lung cancer therapeutics. The increased understanding regarding the various changes observed in non-small cell lung cancer cells that help them further grow is leading to the development of newer drug classes for targeting the changes specifically. Active R&D efforts in this field are also proving beneficial for the overall development of the global non-small cell lung cancer therapeutics market.

Enquiry for Discount @ https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=504

Thanks to continuous efforts and continuous influx of funds into R&D from market players, the market has seen the development of a rich pipeline of innovative drug classes in the past few years. Innovative new generation drugs such as Alecensa (alectinib), which is development by Genentech for the treatment of ALK-positive non-small cell lung cancer, are being approved by a number of drug approval bodies for marketing across the globe. This scenario has also helped a number of new players foray into the market, thus improving the market’s growth prospects.

However, as several highly anticipated drugs are still in the early stages of pipeline, which may take some more time to hit the market, there is a level of uncertainty regarding returns on investment. Moreover, resistance of several cancers to targeted therapies also poses challenges to the further expansion of the market to a certain degree.

More Trending Reports by Transparency Market Research –

Hearing Aids Market: prnewswire.com/news-releases/hearing-aids-market-increasing-prevalence-of-hearing-loss-worldwide-augments-product-demand-says-tmr-300857268.html

Viral Vector and Plasmid DNA Manufacturing Market: globenewswire.com/news-release/2019/04/30/1812834/0/en/Viral-Vector-and-Plasmid-DNA-Manufacturing-Market-is-anticipated-to-surpass-US-2-Billion-by-2027-TMR.html

posted 4 days ago by Bella Watson

  Promote This Article
Facebook Share Button Twitter Share Button Google+ Share Button LinkedIn Share Button Multiple Social Share Button

Related Articles
0 votes

The vendor landscape of the global non-small cell lung cancer therapeutics market features the presence of a number of players, but was dominated by Genentech, a Roche company, which accounted for nearly 36% of the overall market in 2014, observes a recent report by Transparency Market Research (TMR). The market is marked with a moderate level of competition and focus on the development of new and more effective varieties of drugs has increased from companies anticipating a better grip on the market. Strategic collaborations with the view of expanding geographical outreach and product portfolios is also a key strategy adopted by companies operating in the global non-small cell lung cancer therapeutics.

Some of the leading companies operating in the market are Novartis AG, Bristol-Myers Squibb, Celgene Corporation, AstraZeneca plc, Pfizer, Inc., Boehringer Ingelheim, and Eli Lilly and Company.

According to the report, the global non-small cell lung cancer therapeutics market will rise to a valuation of US$15.1 bn by 2023.

Get Sample with Latest Research @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=504

Asia Pacific Promising Excellent Growth Opportunities

Geographically, the market in Asia Pacific is expected to emerge as one of the leading contributors of revenue to the global market, thanks to the rising awareness regarding cancer and the active role of governments in the region in supporting the treatment of lung cancer through subsidized treatment and medicines in public healthcare centers. The region will continue to remain one of the most lucrative regional market for the field of non-small cell lung cancer therapeutics owing to the rising prevalence of lung cancer.

Based on drugs, the segment of angiogenesis inhibitors is expected to dominate in terms of demand as well as revenue contribution to the global market. This can be attributed to its effectiveness and the increased adoption of targeted therapies in a number of regional markets. The segment is expected to rise to a valuation of US$2,020.4 mn by 2023.

Rich Pipeline of Drugs and Continuous R&D Efforts Open Up Promising Growth Avenues for Market

The rising prevalence of lung cancer globally is naturally the leading cause driving the market for non-small cell lung cancer therapeutics. The increased understanding regarding the various changes observed in non-small cell lung cancer cells that help them further grow is leading to the development of newer drug classes for targeting the changes specifically. Active R&D efforts in this field are also proving beneficial for the overall development of the global non-small cell lung cancer therapeutics market.

Buy Now @ https://www.transparencymarketresearch.com/checkout.php?rep_id=504&ltype=S

Thanks to continuous efforts and continuous influx of funds into R&D from market players, the market has seen the development of a rich pipeline of innovative drug classes in the past few years. Innovative new generation drugs such as Alecensa (alectinib), which is development by Genentech for the treatment of ALK-positive non-small cell lung cancer, are being approved by a number of drug approval bodies for marketing across the globe. This scenario has also helped a number of new players foray into the market, thus improving the market’s growth prospects.

However, as several highly anticipated drugs are still in the early stages of pipeline, which may take some more time to hit the market, there is a level of uncertainty regarding returns on investment. Moreover, resistance of several cancers to targeted therapies also poses challenges to the further expansion of the market to a certain degree.

0 votes

The diabetic neuropathy market has witnessed growth from relentless efforts of various healthcare proponents in expanding the array of various therapies and first line drugs in treating the underlying pain. Players have been able to meet the patient needs because of expanding understanding of physiopathology that promote neuropathic pain in diabetes. Most first line drug therapies notably focus on mitigating toxic effects of hyperglycemia. Several players in the diabetic neuropathy market have been benefitting from the introduction of guidelines that help develop therapies that can optimize pain.

The competitive landscape of the diabetic neuropathy market is characterized by fair degree of fragmentation. A handful of players hold sizable shares in the market. Top names in the diabetic neuropathy market are Janssen Pharmaceuticals, Eli Lilly and Company, Cephalon, NeuroMertrix, and Johnson and Johnson. One of the key strategies they increasingly adopt to consolidate their shares is mergers and acquisitions.

During 2017 – 2025, the global diabetic neuropathy market is expected to clock a CAGR of 5.4%. By the end of this period, the worth of the global market is anticipated to be US$5.718 bn.

Request PDF Sample of Diabetic Neuropathy Market Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2199

Prevalence and Complexity Of Diabetic Peripheral Neuropathy Represents Unmet Need

Of the various disorder types, diabetic peripheral neuropathy has attracted the attention of pharmaceutical and biotech companies. By 2025-end, the segment is expected to account for a major share in the global diabetic neuropathy market. The complexity of the type has attracted vast attention of the healthcare industries around the world. The marked prevalence of diabetic peripheral neuropathy adds to its disabling nature. The higher mortality and morbidity of distal symmetrical polyneuropathy is also propelling investments in this area in the global diabetic neuropathy market.

In developed nations, the prevalence of diabetes is increasing at rapid pace. According to recently disclosed statistics by International Diabetes Federation, by 2045 629 million people will be living with diabetes, and currently account for more than 12% of the total spending by adult populations. One of the most complication is diabetic neuropathy. Hence, the condition has attracted groundswell of interest in these nations, such as in the U.S. and the U.K. Further, in recent years, a fast emerging category that is attracting attention of companies in the diabetic neuropathy market is treatment-induced neuropathy in diabetes. Constant advances in understanding of the underlying pathogenesis of diabetic peripheral neuropathy over the last decade have expanded the prospects of the diabetic neuropathy market.

Asia Pacific Fast Emerging as Key Diabetic Neuropathy Market

In the light of developed markets, North America and Europe have emerged as prominent regional markets. A shared factor underpinning the evolution of both these markets are expanding interest in pathophysiological mechanisms. On the other hand, Asia Pacific is emerging as a vastly lucrative region in the global diabetic neuropathy market. This is attributed to the substantial clinical developments in understanding diabetic complications.

Buy Now “Diabetic Neuropathy Market ” Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=2199&ltype=S

Expanding Pharmacological Classes of Drugs Provides New Revenue Base

Lifesciences companies in the global diabetic neuropathy market find it worthwhile and necessary to develop therapies that can target multiple metabolic pathways. Key of these are hyperglycemia, toxic adiposity, mitochondrial dysfunction, and polyol pathway. Promising candidates to emerge in recent years are accumulation of advanced glycation end products (AGEs). Growing research on improving the clinical efficacy of antidepressants and anticonvulsants will likely expand the outlook of the global diabetic neuropathy market. Of note, developed as developed markets are seeing expanding research in pharmacological classes of drugs. The development of these drugs is fueled by the adoption of multimodal and multidisciplinary approaches. Further, growing focus on developing second or third line treatment is also unlocking new potential in the diabetic neuropathy market.

The information shared in this review is based on a TMR report, titled “Diabetic Neuropathy Market (Disorder Type – Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, and Focal Neuropathy; Treatment Type – Drugs (Analgesic (Topical, Opioid, and NSAIDs) Antidepressants (TCAs, SNRIs, and SSRIs; and Anticonvulsant Drugs (Gabapentin, Pregabalin, and Topiramate); Radiotherapy (Transcutaneous Electrical Nerve Stimulation (TENS), and Physiotherapy); Distribution Channel – Hospitals, Clinics, Retail Pharmacy, and Online Pharmacy) – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 – 2025”.

0 votes

Tools and instruments that are available in the clinical microbiology labs for analysis of patient samples and diagnosis are evolving continuously. The main impetus behind this is to reduce the overall time taken to secure results from those lab instruments. In addition to that, increasing the sample turn-around time with the ultimate goal of earlier patient treatment, enhancing the ease of sample processing, and better recovery rates are also comprise the purpose for such evolution. This is particularly true in the case of Antimicrobial Susceptibility Test (AST). It is every hour saved in getting the results lead to an earlier switch to targeted antibiotic therapy that will have a direct influence on the improvement of clinical outcomes.

Global antimicrobial susceptibility test market is likely to observe a surge in its demand owing to overuse of antibiotics in medicine, antibiotic resistance mechanisms has come up as threat to modern medicine by reducing the utility of clinically relevant antibiotics.

Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., HiMedia Laboratories, Biotron Healthcare, Beckman Coulter, and Creative Diagnostics are some of the leading names that operate in the global antimicrobial susceptibility test market.

Request PDF Sample of Antimicrobial Susceptibility Test Market Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=31508

According to a new study by Transparency Market Research (TMR), it is predicted that the global antimicrobial susceptibility test market will expand at a growth rate of 4.6% CAGR between 2017 and 2025. Global antimicrobial susceptibility test market is estimated to reach US$ 3814.0 mn by the end of the forecast period that spans from 2017 to 2025.

Increased Government Initiatives to Prevent Antibiotic Resistance Fuels North American Market

North America is expected to be the retain the position of the most promising market in the global antimicrobial susceptibility test market owing to the emergence of a multidrug resistant strain of Salmonella in the US. For example, in accordance with the report by Centers for Disease Control and Prevention (CDC), around 2 million people in the US were infected with antibiotic-resistant bacteria annually and 23,000 people died as a result of such infection.

Furthermore, government agencies in the US have taken the onus to control and prevent antibiotic resistance, which is anticipated to accelerate the adoption of antimicrobial susceptibility test in the country.

Enquiry for Discount on “Antimicrobial Susceptibility Test Market” Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=31508

Antimicrobial susceptibility test market in Asia Pacific is estimated to witness substantial growth during the period of forecast, 2017 to 2025. The market is expected to thrive on increased prevalence of microbial infections and rising consumption of antibiotics that eventually leads to development of resistance amongst the people. According to a report by WHO prevalence of multidrug –resistant tuberculosis is quite high though the treatment is very limited. Such factors trigger the growth of antimicrobial susceptibility test market in the region.

Improved Knowledge of Molecular Mechanisms Needed to Control Multidrug Resistance

In the recent years, there has been a drastic rise in the antibiotic resistance amongst bacterial pathogens and this is regarded as one of the biggest threats to global health in the current era. Globally, antibiotic resistance leads to 700,000 deaths each year and medical experts estimate the number could grow to 10 million deaths per year by 2050. Unless stringent actions are taken to check the misuse and overuse of antibiotics, antibiotic resistance will wreak havoc worldwide.

Data also hint that, though antibiotic resistant bacterial infections can occur in the community but most deaths owing to resistance take place in various in-patient healthcare settings such as nursing homes and hospitals. In a hospital setting, when a patient displays signs of infection such as sepsis, they are quickly put on empiric broad spectrum antibiotics. Current literature suggests that around 51% of the patients in general wards and nearly 82% of the patients in Intensive Care Units (ICUs) are already on antibiotics within 4 hours prior to collection of blood samples for culture.

Government healthcare regulatory agencies are proactively implementing measures essential to reduce or control its prevalence. In July 2018, the UK Standards for Microbiology Investigation (UK SMIs) made a recommendation of a core set of antibiotic susceptibilities, which should be set up for a variety of bacterial species isolated from various types of specimen.

Besides, enhanced knowledge of molecular mechanisms that control multidrug resistance is forecasted to facilitate the development of novel therapies, which would combat intractable infections and assist in the cultivation of a deeper understanding of the pathobiology of microbial organisms. Several awareness programs are being conducted to facilitate proper usage of new drugs to re-establish dominance over diseases.

0 votes

The global rheumatology therapeutics market is highly competitive and consolidated due to presence of strong players, finds Transparency Market Research (TMR). Some of the key players operating in the global rheumatology therapeutics market are AbbVie, Inc., Bristol-Myers Squibb Company, Pfizer, Inc., Merck & Co., Inc., Amgen, Inc., Novartis AG, Janssen Biotech, Inc., Sanofi, Genentech, Inc., and Takeda Pharmaceutical. Among them, the companies such as AbbVie, Inc., Bristol-Myers Squibb Company, Pfizer, Inc., and Merck & Co., Inc. are accounts for the leading share in the global rheumatology therapeutics market.

TMR anticipated the global revenue of the rheumatology therapeutics market was registered in 2016 US$41.88 bn and expected to expand with a CAGR of 2.7% over the forecast period from 2017 to 2025 and expected to attain value of a US$ 52.96 bn by the end of 2025. On the basis of drug class, the segment biologic DMARDs has registered at the revenue of US$35.83 bn in 2016 is expected to rise at a 2.6% CAGR with this growth rate in a revenue of US$45.06 bn by 2025. This growth is attributable to high usage of Azathioprine, cyclosporine, cyclophosphamide, and methotrexate. On the basis of region, North America accounts for a leading share in the global rheumatology therapeutics market owing to rapid rise in the elderly population.

Request PDF Sample of Rheumatology Therapeutics Market Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1494

Rising Prevalence of Rheumatology Diseases to Boost Growth

Rheumatology diseases generally effects on the supporting and connecting structures and bones of the body such as joints, muscles, ligaments, tendons and some of the organs of body. It is characterized by effects on spine and inflammation of joints occurred in some of the symptoms of rheumatology disease. Early diagnosis and treatment on symptoms of rheumatology disease. Physicians generally prescribe disease-modifying anti-rheumatic drugs (DMARD’s) for treatment of rheumatologic disease. Rising prevalence of rheumatology diseases are boosting requirement of its treatments which is fuelling growth of the global rheumatology therapeutics market.

Additionally, technological advancements in pharmaceutical field coupled with increasing investments in healthcare industry for research and development activities. Rising trend for fitness globally which is expected to support the growth of rheumatology therapeutics market. Increasing expenditure on healthcare from mid-earing population is driving growth of the global rheumatology therapeutics market.

Buy Now “Rheumatology Therapeutics Market ” Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=1494&ltype=S

Availability of Alternatives for Rheumatology Therapeutics to Hamper Growth

However, launch of biosimilars is key factors hampering growth of the rheumatology therapeutics market. Rising demand for biosimilar products are crimping growth of the rheumatology therapeutics market. Additionally, patent expiry of well-known drugs used in the treatment of rheumatology diseases is hampering growth of the rheumatology therapeutics market. Nevertheless, increasing launches of novel biologics drugs and rising penetration of generic drugs are expected to drive growth of the market. Increasing approvals for new biologics such as Xeljanz are anticipated to account for high penetration which is likely to create opportunities in the global rheumatology therapeutics market.

More Trending Reports by Transparency Market Research –

Tissue Engineered Skin Substitutes Market: globenewswire.com/news-release/2019/01/23/1704315/0/en/Tissue-Engineered-Skin-Substitutes-Market-to-reach-around-US-3-87-billion-by-2023-TMR.html

Collagen Market: globenewswire.com/news-release/2019/05/15/1825247/0/en/Collagen-Market-to-Expand-at-a-CAGR-of-9-4-by-2023-Marine-Collagen-to-Gain-Maximum-Prominence-Says-TMR.html

0 votes

A recent report on extracorporeal membrane oxygenation machine market is published by Transparency Market Research. The market features a fragmented competitive landscape because of the presence of several notable and well-established companies. There are multiple small and medium sized companies that are now gaining entry in the global market. It is projected that the established players in the global extracorporeal membrane oxygenation machine market would resist in the emergence of these new players in order to maintain their brand position in the market. These leading companies are expected to focus on aggressive business strategies such as mergers, joint ventures, and acquisitions in order to stay ahead of the competitive curve. Moreover, they are also expected to pay more attention to the development of new and innovative products in order to stay relative in the market.

Product Development is Key for Revenue Generation

There are a few barriers for the entry of a new company entering in the global extracorporeal membrane oxygenation machine market. However, huge initial investment and high levels of skill set are mandatory to sustain in the global market in the long term. In recent years, several new and innovative products have been introduced by these leading companies and is expected to be the go to strategy for their growth and development. Since these innovative and new technologies are being increasingly adopted by the end-users, the market players are projected to enjoy considerable profits with the help of high-tech product lines. Acquiring smaller and emerging players is key for this strategic approach. Some of the leading companies operating in the global extracorporeal membrane oxygenation machine market include names such as MicroPot Scientific Corporation, Medtronic Plc., LivaNova Plc., and Getinge AB among others.

Request Sample @ 

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=22187

With such aggressive business strategies adopted by the global extracorporeal membrane oxygenation machine market players, it is inevitable that the market will experience a high growth. According to the TMR report, the extracorporeal membrane oxygenation machine market will exhibit an impressive CAGR of 5.40% for the given period of forecast of 2017 to 2025. Initially, the global market was valued at US$307.00 mn in 2016. With this rate of growth, the global market is expected to jump to a valuation of US$487.40 mn by the end of 2025.

Request Brochure @ 

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=22187

Increasing Adoption of New Tech to Push North America Market Growth

In terms of geographical segmentation, the global extracorporeal membrane oxygenation machine market is expected to be led by the North America region. With the availability of highly developed healthcare infrastructure and increasing acceptance of new technology, the extracorporeal membrane oxygenation machine market will thrive more in the North America region.

...